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Department of Medicine, University of Massachusetts Medical School, Worcester, USASummary dNTPase activity, and an N-terminal CARD, pyrin (PYD), BIRInﬂammation is a common element in the pathogenesis of most
chronic liver diseases that lead to ﬁbrosis and cirrhosis. Inﬂam-
mation is characterized by activation of innate immune cells
and production of pro-inﬂammatory cytokines IL-1a, IL-1b, and
TNFa. Inﬂammasomes are intracellular multiprotein complexes
expressed in both parenchymal and non-parenchymal cells of
the liver that in response to cellular danger signals activate cas-
pase-1, and release IL-1b and IL-18. The importance of inﬂamma-
some activation in various forms of liver diseases in relation to
liver damage, steatosis, inﬂammation and ﬁbrosis is discussed
in this review.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Inﬂammasomes and their signal transduction pathways
The term ‘‘inﬂammasome’’, introduced by Tschopp and col-
leagues [1] refers to large multiprotein complexes that sense
intracellular danger signals via NOD-like receptors (NLR) [2].
NOD-like receptors, members of the pattern recognition
receptor family, contain a C-terminal leucin-rich-repeat (LRR)
domain that plays a role in the recognition of ligands, a central
NACHT domain that is responsible for the oligomerization andJournal of Hepatology 20
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Based on the NACHT domain, three subfamilies of proteins are
deﬁned: (a) NODs, (NOD1–5, CIITA), (b) NLRPs or NALPs (NLRP/
NALP 1–14), and (c) IPAF (IPAF, NAIP) subfamily [2] (summarized
in Fig. 1). Other classiﬁcations, based on the N-terminal effector
domain, are also known [3]. Several, but not all, NLRs play a role
in the formation of inﬂammasomes. With the exception of AIM2,
which is a member of the HIN-200 family, the nomenclature of
inﬂammasomes is based on the NOD-like receptor (NLR).
Key Points 1 
Nod like receptors (NLRs) contain a C-terminal leucin-rich-
repeat (LRR) domain that plays a role in the recognition of 
ligands, a central NACHT domain that is responsible for the 
oligomerization and dNTPase activity, and an N-terminal 
CARD, pyrin (PYD), BIR (baculoviral inhibitory repeat), 
or acidic transactivation domain. NLRs have been 
grouped into subfamilies by either the NACHT domain or 
the N-terminal domain. Several, but not all, NLRs play a role 
masome. In addition, non-NLR proteins, such as AIM2 can 
also form a complex with caspase-1
in the formation of a multiprotein complex called the inflam-
The sensor, NLR, forms a complex with the effector molecule,
pro-caspase-1, with or without the contribution of an adapter
molecule, such as the apoptosis-associated speck like CARD-
domain containing protein (ASC) [1–4]. Inﬂammasome activation
leads to auto-activation of the 45 kDa inactive pro-caspase-1 pre-
cursor into p20 and p10 subunits that form the active caspase-1
[1–4], resulting in the cleavage of pro-IL-1b and pro-IL-18 into
mature forms, and inactivation of IL-33 [1–5]. IL-1b is a pro-
inﬂammatory cytokine, a central regulator of inﬂammation that
binds to the IL-1 receptor (IL-1R) to exert its broad biological
effects. IL-1R also recognizes IL-1a and binds IL-1R antagonist
(IL-1Ra), the latter inhibiting IL-1R activation [6]. IL-18 activates
natural killer (NK) cells to produce IFNc [6], while IL-33 is a chro-
matin-associated cytokine of the IL-1 family that drives Th2
responses [4,6]. The full-length active IL-33 is cleaved and inacti-
vated by caspase-1 [5].
Inﬂammasome activation is thought to be a two-step process
in which signal 1 (mostly from TLR activation) upregulates
inﬂammasome expression and signal 2 triggers functional
inﬂammasome activation by an inﬂammasome ligand [2,4]. A
recent publication suggests that the priming step is required only
for activation of NLRP3 and not other inﬂammasomes such as12 vol. 57 j 642–654
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Fig. 1. Structure of inﬂammasome and non-inﬂammasome NLRs and non-
NLR inﬂammasomes.
Table 1. Known activators of inﬂammasome NLRs.
Activator
NLRP1 (NALP1) Bacillus anthracis lethal toxin [8-11]
MDP [10,11]
NLRP3 (NALP3, cryoporin) Large particles via phagocytosis
Monosodium urate crystals (MSU) [12
CPPD (calcium pyrophosphate dehyd
Alum [13]
Silica [14]
Asbestos [15]
Amyloid beta [16]
Hyaluronan [17]
Hemozoin [18]
Vaccine adjuvants (poly lactide-co-gly
Cholesterol crystals [20]
Bacterial toxins (pore-forming)
Listeria monocytogenes Lysteriolysin 
Staphylococcus aureus alpha-toxin [2
Aeromonas hydrophila aerolysin [21,2
Streptolysin [24]
Nigericin [21]
Ion channels and activators
ATP(P2X7) [21]
PAMPs (only if transferred to the cyto
LPS, lipid A, PGN, MDP, LTA, Pam3,
NLRC4 (IPAF)
Salmonella typhymurium [28]
[28,29]
Legionella pneumophila [30]
Pseudomonas aeruginosa [28]
AIM2 dsDNA
bacterial [31,32]
viral [31,32]
mitochondrial [33]
host [31]
lnflammasome
Maitoxin (Dinoflagellates) [22]
lnfluenza virus M2 channel protein [25
Gram - negative bacteria (flagellin-d
Shigella flexneri
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Journal of Hepatology 201NLRC4 or AIM2 [7]. Inﬂammasome ligands include both patho-
gen-associated (PAMPs) and endogenous danger molecules
(DAMPs) (summerized in Table 1) [1–4]. To date, four main pro-
totypes of inﬂammasomes have been characterized: NLRP1
(NALP1); NLRP3 (NALP3, cryporin); NLRC4 (IPAF) and AIM2
[2,4]. They have different ligand recognition sites and utilization
of adapter molecules but all culminate in caspase-1 activation.
NLRP1 inﬂammasome
NLRP1 (NACHT, LRR, and PYD domains-containing protein 1), the
ﬁrst inﬂammasome described, can directly interact with caspase-
1 through its C-terminal CARD domain, and in humans, the pres-
ence of ASC enhances the activity of the complex [34]. Murine
NLRP1 is unable to bind to ASC because it lacks a functional
PYD domain [34]. Multiple alternatively spliced transcript vari-
ants of human NLRP1 exist [35].
NLRP1 is activated by the muramyl dipeptide (MDP) and the
Bacillus anthracis lethal toxin [8–11]. An interaction was reported
between NLRP1 and another NLR protein, NOD2, and Hsu et al.
found that NLRP1 and NOD2 were both required for MDP or B.
anthracis toxin-induced IL-1b secretion [11]. Potassium efﬂux
plays a role in NLRP1 inﬂammasome activation [9] and NLRP1
can localize into the nucleus, and this feature is unique in]
rate) [12]
colide and polystyrene microparticles) [19] 
O [21,22]
1-23]
2]
plasm by e.g. Streptolysin O pore-forming toxin)
 ssRNA, dsRNA, CpG DNA  [26,27]
]
ependent and independent)
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comparison to the cytoplasmic distribution of other inﬂamma-
somes [36].
Key Points 2 
intracellular, multiprotein complexes that sense danger 
and activation lead to autoactivation of caspase-1 that in 
turn cleaves pro-IL-1β, pro-IL-18 into their mature form, 
inactivates IL-33 and regulates cell death and survival. 
NLRP3, NLRC4 and AIM2. They have different recognition 
PAMPs or DAMPs is usually a 2-step process
Inflammasomes, the members of PRR family, are large
signals via NOD-like receptors. Inflammasome priming
The four main prototypes of inflammasomes are NLRP1,
sites and ligand specificity and all culminate in caspase-1
activation. The activation of the inflammasomes by eitherNLRP3 inﬂammasome
NLRP3 (NACHT, LRR, and PYD domains-containing protein 3, cry-
oporin) was ﬁrst described by Hoffman et al. who discovered four
single mutations in the NLRP3 gene, in families with familial cold
autoinﬂammatory syndrome and Muckle–Wells syndrome,
which lead to increased IL-1b production [37]. Later, Agostini
et al. reported that NLRP3 forms an IL-1b-processing inﬂamma-
some complex [38]. To date, NLRP3 is the most fully character-
ized member of the inﬂammasome family. It consists of the
NOD-like receptor NLRP3, the adaptor molecule ASC, and the
effector molecule pro-caspase-1. Since NLRP3 does not contain
a CARD domain, the presence of the adaptor molecule is neces-
sary for the complex formation [34].
The expression of NLRP3 is tightly regulated at the transcrip-
tional level via NFjB [39]. NLRP3 activation requires two signals.
Cell priming with an NFjB activator, such as the TLR4-ligand LPS,
is the ﬁrst step of NLRP3 inﬂammasome activation [39] leading to
up regulation of NLRP3 expression [39] while the second signal
includes a broad variety of activators.
Three major pathways have been implicated in NLRP3 inﬂam-
masome activation (Fig. 2) induced by a wide variety of activators
[12–27]. First, extracellular ATP sensed by the P2X7 purinergic
receptor results in potassium efﬂux and recruitment of pannexin
that induces NLRP3 activation [21,26,40]. Pannexin is a mem-
brane pore that allows the delivery of extracellular PAMPs and
DAMPs into the cytosol [26].
Second, NLRP3 activation is induced by crystals or large parti-
cles such as silica, asbestos, aluminium, amyloid, monosodium
urate, and cholesterol [12–20]. It has been shown that disruption
of lysosomes by chemical damage [41] or lysosomal damage after
phagocytosis of these large particles induces NLRP3 inﬂamma-
some activation [14,16,20]. Consistent with the role of lysosomal
damage in inﬂammasome activation, the role of a lysosomal pro-
tease, cathepsin B, has been implicated in certain forms of NLRP3
activation [4,18,42].
Third, some studies suggest that reactive oxygen species (ROS)
contribute to inﬂammasome activation. This is based on the
observation that inhibitors or scavengers that block mitochon-
drial ROS or NADPH oxidase suppress inﬂammasome activation
[4,15,43–45]. ROS induction may represent a common pathway
from different cellular insults. For example, large particles [43]
and ATP [44], that are known ‘‘inﬂammasome-activators’’, induce
ROS production. ROS-dependent release of thioredoxin-interact-644 Journal of Hepatology 201ing protein (TXNIP) from thioredoxin and direct interaction
between TXNIP and NLRP3 have been described [45]. However,
ROS production does not always result in inﬂammasome activa-
tion [4,7,14,34] and NLRP3 activation is not impaired in macro-
phages deﬁcient in NADPH oxidase subunits [46,47]. In addition
Bauernfeind et al. showed that ROS inhibitors blocked priming
and not activation of the NLRP3 inﬂammasome [7].
NLRC4 inﬂammasome
NLRC4/IPAF (NLR-family CARD domain containing protein 4)
inﬂammasome is activated by the ﬂagellin of Gram-negative
and Gram-positive bacteria [28–30] or the type III secretion sys-
tem (T3SS) of Gram-negative bacteria [28–30]. The steps of
NRLC4 inﬂammasome activation are not yet fully explored. Zhao
et al. have reported that other NLR proteins, such as murine
NAIP5 and NAIP2, interact with the bacterial ﬂagellin or type III
secretion system (T3SS) rod components, respectively, and pro-
mote the assembly and activation of NLRC4 inﬂammasome
[48]. Human NAIP recognizes the T3SS needle subunit [48].
AIM 2 inﬂammasome
AIM 2 (absent in melanoma 2) is a cytosolic dsDNA sensing
inﬂammasome [31–33] activated by bacterial, viral, and mamma-
lian host DNA to trigger caspase-1 activation [31–33]. AIM2 can
directly bind to its ligand [32] and may contribute to the patho-
genesis of autoimmune diseases by recognizing the mammalian
DNA [49]. Caspase-1 activation can also occur as a result of inﬂam-
masome activation by dsRNA via the helicase receptor RIG-I, after
association with the inﬂammasome adaptor molecule ASC [50].Secretion of interleukin-1b
Activation of inﬂammasomes culminates in caspase-1 activation
and IL-1b secretion. Early observations suggested that IL-1b was
secreted independently of the ‘‘classical’’ endoplasmatic reticu-
lum-Golgi route [51]. The molecular mechanisms of IL-1b secre-
tion are yet to be clariﬁed. Some studies suggested that
caspase-1 was present in secretory lysosomes together with
other lysosomal proteins and pro-IL-1b [52]. Andrei et al.
reported that ATP-triggered potassium efﬂux led to calcium-
dependent phospholipase C activation, followed by activation of
phospholipase A2 and eventually exocytosis and IL-1b release
[52]. Recently, pyroptosis has been suggested as an alternative
mechanism for IL-1b release [53].
Importantly, IL-1 production has an auto-regulatory loop. The
secreted active IL-1b or IL-1a can activate the IL-1 receptor com-
plex and increase the transcription of its own precursor as well as
the synthesis of the inﬂammasome components [53–55,39]. This
ampliﬁcation loop suggests that small amounts of IL-1b could
have a signiﬁcant biological effect.Inﬂammasomes regulate cell fate
Increasing evidence suggests important, IL-1b- and IL-18-inde-
pendent, ‘‘non-canonical’’ roles of inﬂammasomes that have been
recently reviewed by Lamkanﬁ [56]. In addition to inﬂammation,
inﬂammasome activation regulates cell death [56,57]. NLRP1,
NLRC4 (IPAF), and NAIP activate pyroptosis, while NLRP3 activa-2 vol. 57 j 642–654
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Fig. 2. Inﬂammasome activating pathways.
JOURNAL OF HEPATOLOGYtion contributes to pyronecrosis [57]. Pyroptosis is a caspase-1-
dependent cell death showing similarities to apoptosis and DNA
damage. Unlike apoptosis, pyroptosis does not depend on apop-
totic caspases and it is accompanied by loss of plasma membrane
integrity and lack of chromatin condensation [57]. Pyronecrosis
shows similarities to necrosis since it is not caspase dependent
and leads to breakdown of the plasma membrane without chro-
matin condensation. NLRP3-induced pyronecrosis utilizes theJournal of Hepatology 201adaptor molecule ASC, and involves the lysosomal enzyme
cathepsin B [57]. The loss of plasma membrane integrity might
lead to the secretion of various dangerous molecules. Both pyrop-
tosis and pyronecrosis elicit inﬂammation thereby linking various
forms of cell death to innate immune activation. Most recently,
Motani et al. have described an ASC-dependent necrosis that is
independent of the catalytic activity of caspase-1, but is still
inhibited by long-term caspase-1 knockdown [58]. Interestingly,2 vol. 57 j 642–654 645
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a study in HeLa and Chinese hamster ovary (CHO) cells suggests
that inﬂammasome activation and caspase-1 may promote cell
survival via sterol regulatory element binding proteins (SREBPs)
and lead to membrane repair and healing [22].Inﬂammasomes and interleukin-1b in autoinﬂammatory
diseases
The pathogenic role of IL-1b and inﬂammasomes has been impli-
cated in several autoinﬂammatory diseases [53]. Furthermore,
the role of inﬂammasome activation and IL-1 is becoming a focus
of investigation in chronic inﬂammatory conditions including
metabolic, neurological, and gastrointestinal disorders. Various
pharmacologic agents are available to inhibit IL-1b (or IL-1a)
activity: IL-1 receptor antagonist (anakinra); soluble IL-1 receptor
(rilonacept); IgG1 type anti-IL-1b (canakinumab); IgG2 type anti-
IL-1b (Xoma 052) and anti-IL-1R MoAb IgG1 (AMG108). Dinarello
has recently reviewed the available anti-inﬂammatory agents
[53,59]. Beyond the anti-IL-1b therapies, there are ongoing clini-
cal trials with caspase-1 inhibitors and P2X7R blockers [60,61]; of
these, the latter failed to improve the symptoms of rheumatoid
arthritis [61].
Key Points 3 
The role of IL-1β has been implicated in several auto-
diseases that respond to anti-IL-1β therapy, grouping 
Mediterranean Fever, CAPS, Hyper IgD syndrome, Still’s 
disease, Behçet’s diseases, Schnitzler’s syndrome, 
TNF-receptor-associated periodic syndrome), probable 
syndrome, urticarial vasculitis, anti-synthetase syndrome, 
relapsing chondritis, PAPA syndrome, Blau’s syndrome, 
Sweet’s syndrome) and common, IL-1β-mediated diseases 
(gout, rheumatoid arthritis, osteoarthritis, type 2 diabetes, 
smoldering multiple myeloma, post-myocardial infarction 
heart failure and PFAPA) [53]
inflammatory diseases, that were recently reviewed by
Dinarello. He summarized the auto-inflammatory
them as classic auto-inflammatory diseases (Familial
auto-inflammatory diseases (macrophage activationCell-speciﬁc expression of inﬂammasomes in the liver
While marked constitutive expression of caspase-1 has been
reported in the liver [62], the expression of inﬂammasomes and
the subcellular localization of the different NLRs vary between
tissues [36]. Early studies showed the highest expression of
NLRP3 (CIAS1) and NLRP1 (NAC) in peripheral blood leukocytes,
while the liver showed relatively low levels [63,64]. Recent stud-
ies have suggested that the liver expresses NLRP1, 2, 3, 6, 10, 12,
and NLRC4 at the mRNA level [65]. Compared to the spleen,
human livers express higher levels of NLRP10 [65], while murine
livers express higher levels of NLRP6 [65].
Key Points 4 
in the liver in hepatocytes, liver sinusoidal endothelial cells, 
hepatic stellate cells and macrophages 
Inflammasomes are expressed and likely functionally active646 Journal of Hepatology 201The liver is comprised of both parenchymal (hepatocytes) and
immune cells (macrophages, neutrophil leukocytes, dendritic
cells, T cells, NK/NKT cells, B lymphocytes), where hepatocytes
represent the majority of the cell populations. Innate immune
cells, including monocytes, macrophages, neutrophils, and den-
dritic cells, express inﬂammasomes and there is increasing evi-
dence that inﬂammasomes exist and are functionally active in
non-immune cells, including hepatocytes [66–68], stellate cells
[69], endothelial cells [70,71], and myoﬁbroblasts [72]. Hepato-
cytes, bile duct epithelial cells and stellate cells express ASC pro-
tein [36,69,73]. The liver resident macrophages, Kupffer cells,
produce signiﬁcant amounts of IL-1b [74] and express most of
the NLRs (Petrasek and Szabo, unpublished data), although NLRP1
expression was absent in one study [36]. The presence of NLRP3
inﬂammasome and/or inﬂammasome activation has been shown
in sinusoidal endothelial cells [71], stellate cells [69], and hepato-
cytes [66–68,75]. The cell-speciﬁc expression of the inﬂamma-
some components in the liver is summarized in Fig. 3.The role of inﬂammasomes in liver diseases
The below detailed potential triggers of inﬂammasomes in liver
diseases are summarized in Fig. 4.
Drug-induced liver injury (DILI)
Acetaminophen (APAP)-induced liver injury remains the leading
cause of DILI. In APAP-induced liver damage, release of DAMPs
from necrotic hepatocytes and sinusoidal endothelial cells [76]
triggers sterile inﬂammation via pattern recognition receptors
including TLRs (e.g. apoptotic DNA) and NLRs/inﬂammasomes
(e.g. ATP, MSU) [77]. However, reports are controversial on the
role of inﬂammasomes and IL-1b in the pathogenesis of APAP-
induced liver injury. In a small study in children and adolescents,
APAP overdose was not associated with increased serum IL-1b
levels [78], while the majority of reports found increased IL-1b
mRNA and protein levels in the liver and serum of animal models
[71,79–85]. The question of whether the relatively low increases
in IL-1b levels could explain APAP-induced liver damage remains
under debate. Several studies examined the functional role of IL-
1b and IL-18, another inﬂammasome-dependent cytokine, in
APAP-induced liver failure. Chen et al. found that IL-1R deﬁciency
resulted in attenuation of APAP-induced liver injury indicated by
the lower ALT levels and reduced neutrophil recruitment [82].
Blocking antibodies against IL-1a, IL-1b, and IL-1R also lead to
attenuation of the APAP-induced liver failure, however, the
extent of protection was milder than in the IL-1R deﬁcient mice
[82]. Consistent with this observation, administration of IL-1b
neutralizing antibodies and use of IL-18 KO mice also increased
survival after a lethal dose of APAP administration [71]. It has
been proposed that apoptotic DNA from damaged cells results
in pro-IL-1b mRNA production via TLR9, and that together with
other DAMPs induce inﬂammasome activation [71,77]. Imaeda
et al. found that APAP liver injury was attenuated in mice lacking
components of NLRP3 inﬂammasome (ASC, NLRP3, caspase-1),
but not NLRC4 (IPAF), suggesting a role for NLRP3 inﬂammasome
in APAP-induced liver injury [71]. In contrast, Williams et al.
reported that IL-1R KO mice, or mice lacking inﬂammasome com-
ponents (caspase-1, ASC, NLRP3) showed no protection, and
administration of a pan-caspase inhibitor also failed to prevent2 vol. 57 j 642–654
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APAP-liver injury while it blocked IL-1b increase [81,83]. These
contradictory observations may be related to the complex role
of inﬂammasome and IL-1b signaling that extends beyond
inﬂammation to cell death. Another consideration is the timing
of the interventions in relation to the APAP injury, and age and
gender differences between animal models. Beyond IL-1b, the
role of IL-1a should also be considered in APAP toxicity as IL-
1a levels are also increased [79]. To further complicate the pic-
ture, IL-1R antagonist-deﬁcient mice showed reduced liver injury
in response to APAP overdose. This might be explained by the
observation that IL-1Ra KO mice generated less toxic metabolites
(NAPQI) than wild type mice [85]. Finally, the cell speciﬁcity of
inﬂammasome activation and IL-1b production is only partially
understood. Inﬂammasome activation was shown to result in
IL-1b production in sinusoidal endothelial cells after APAP expo-
sure [71] and in RAW264.7 macrophages, suggesting that multi-
ple cell types are affected [86].
Key Points 5 
been implicated in the pathogenesis of acute liver injury 
induced by acetaminophen, ischemia/reperfusion or 
endotoxin, as well as in chronic liver diseases with 
increased gut permeability, including alcoholic and non-
in the pathogenesis of infectious diseases of the liver, 
including hepatitis C virus infection and Schistosomiasis. 
may contribute to the progression of the liver diseases 
in liver diseases are summerized in Figure 4
The role of IL-1 signaling and inflammasomes has
alcoholic steatohepatitis. Inflammasomes also play a role
In addition, inflammasome activation and/or IL-1 signaling
regulating fibrosis. The potential triggers of inflammasomeIschemia–reperfusion
Ischemia–reperfusion (I/R) has clinical relevance to liver trans-
plantation, partial hepatectomy, and hypovolemic shock [87].
The characteristics of I/R are hepatocyte death, release of DAMPs,
inﬂammatory cell inﬁltration, Kupffer cell activation, ROS pro-
duction, and disruption of liver sinusoidal endothelial cells (LSEC)
that can all lead to inﬂammasome activation [88]. Silencing
NLRP3 ameliorated I/R-induced hepatocellular injury and reduced
IL-1b, IL-18, HMGB1, IL-6, and TNFa release via inhibition of cas-
pase-1 and NFjB activity [89]. Consistent with this, decreased
caspase-1 activation was found in the presence of the antioxidant
N-acetylcysteine, in I/R injury [75].
Involvement of caspase-1 (ICE) and apoptosis were observed
during the re-oxygenation phase in contrast to the predomi-
nantly necrotic features in the hypoxic phase [75]. Caspase-1
activation was present during hypoxia and during the re-oxygen-
ation phase, and a speciﬁc caspase-1 inhibitor (YVAD) prevented
I/R-induced cell death [75]. The role of the inﬂammasome/cas-
pase-1 system in I/R injury is further supported by observations
where IL-1R antagonist pretreatment, delivery of an IL-1 receptor
antagonist (IL-1Ra) cDNA into the liver, or IL-18 neutralizing anti-
bodies signiﬁcantly reduced liver damage, inﬂammation, and
mortality in animal models [90–92]. Notably, TLR4 and TLR9,
both of which control IL-1b and NLRP transcription, play a role
in I/R liver injury [93,94].Journal of Hepatology 201Recent ﬁndings suggested that caspase-1 was hepatoprotec-
tive in a trauma model [95]; however, NLRP3-independent cas-
pase-1 activation was found in hemorrhagic shock and trauma
in I/R injury.
Endotoxin-induced liver injury and cholestasis
Endotoxin (lipopolysaccharide (LPS)), a cell wall component of
Gram-negative bacteria, is a major mediator of sepsis-induced
liver damage, multi-organ failure, and chronic liver disease.
Owing to the portal blood supply arriving from the intestines
and its unique microcirculation, the liver is exposed to high con-
centrations of nutrients and gut-derived substances including
LPS. The role of the gut microbiota, increased intestinal perme-
ability and portal endotoxinaemia has been described in several
liver diseases [96].
LPS, a ligand of TLR4, is a potent inducer of mRNA expression
of all inﬂammasome components (NLRP3, ASC, caspase-1 and
pannexin-1), pro-IL-1b and pro-IL-18 via NFjB activation
[39,97], although TLR-independent, LPS-induced upregulation of
inﬂammasome has also been described [26]. In mice, in vivo
LPS administration increased the mRNA expression of the compo-
nents of the inﬂammasome as well as serum and liver mature IL-
1b levels, indicating caspase-1/inﬂammasome activation [97].
Priming with heat-killed Proprionibacterium acnes induced
liver inﬂammatory cell aggregates and rendered mice susceptible
to LPS-induced liver injury [98,99]. IL-18 and IL-1b played a role
in this process [100–107] and Kupffer cell depletion could atten-
uate the P. acnes/LPS-induced liver injury [102,106]. In this
model, LPS challenge resulted in NLRP3-mediated caspase-1 acti-
vation in Kupffer cells in a TRIF-dependent manner without
affecting the ATP/P2X7R pathway [106]. In TRIF KO mice, hepatic
granulomas, but no IL-18 release or liver injury, were present.
MyD88, the common TLR adaptor, was crucial for the transcrip-
tional regulation of IL-18 and IL-1b, but not for their maturation
and release [106]. NLRP3- and ASC-deﬁcient mice were also resis-
tant to P. acnes and LPS-induced liver injury and failed to secrete
IL-18 [106]. The effector role of IL-1/IL-1R signaling in LPS-
induced liver injury was suggested by the observation that IL-
1Ra pretreatment attenuated the liver injury [107].
Kupffer cells were identiﬁed as the main source of LPS-
induced IL-1b and IL-18 [102,106], and caspase-1-deﬁcient Kupf-
fer cells were not able to secrete mature IL-1b or IL-18 upon LPS
stimulation [105]. A potential role for other cell types cannot be
excluded because in one study depletion of macrophages resulted
in only moderate amelioration of the liver injury and it did not
inﬂuence IL-18 levels [108].
Alcoholic and non-alcoholic fatty liver diseases
There is increasing evidence that gut microbiota, increased gut
permeability and endotoxin contribute to the pathogenesis of
both alcoholic (ASH) and non-alcoholic steatohepatitis (NASH)
[96]. In alcoholics with liver disease, as well as in animal models
of alcohol-induced liver disease, serum levels of IL-1b were
increased [109,110]. Hsiang et al. showed IL-1b and TNFa secre-
tion from HepG2 hepatocytes treated with acetaldehyde, a meta-
bolic product of alcohol [111]. In a mouse model of chronic
alcohol feeding, we found increased serum and liver mature
IL-1b (17 kDa) levels, increased caspase-1 activation and upregu-
lation of the inﬂammasome components, NLRP3, ASC, and2 vol. 57 j 642–654 647
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Fig. 3. Cell-speciﬁc inﬂammasome expression in the liver.
Reviewpro-caspase-1 in the liver (Petrasek and Szabo, manuscript under
review) suggesting that inﬂammasome activation is a component
of the liver pathophysiology in ALD.
The role of inﬂammasomes and IL-1b in the metabolic syn-
drome and NASH is receiving increasing attention [66,74,112–
118]. IL-1b protein and mRNA levels are increased in various
diet-induced NASH models in mice, including methionine–cho-
line-deﬁcient (MCD), high fat (HF) and choline-deﬁcient amino
acid-deﬁned (CDAA) diets [66,74,112–118]. Inﬂammasome acti-
vation was associated with steatohepatitis (NASH) [66,113] but
not with steatosis alone as it occurs in leptin-deﬁcient mice or
after short-term high fat diet feeding [66]. IL-1R KO mice showed
attenuated liver injury, steatosis, and ﬁbrosis in the CDAA and HF
diet-models [74,117]. IL-1b KO mice also had attenuated hepato-
cellular damage, steatosis, and ﬁbrosis in atherogenic diet-
induced steatohepatitis [114]. IL-1a may also contribute to the
pathogenesis of NASH as IL-1a KO mice also showed attenuated
liver damage and ﬁbrosis in a HF diet-induced steatohepatitis
model [114]. IL-1R antagonist (IL-1Ra)-deﬁcient mice showed
severe hepatic fat accumulation and ﬁbrosis when kept on an
atherogenic diet as compared to wild type controls [118]. Consis-
tent with inﬂammasome involvement, long-term high fat diet
administration resulted in reduced hepatic steatosis in NLRP3
KO mice [113]. In db/db mice fed an MCD diet, administration
of a pan-caspase inhibitor, VX-166, prevented mature IL-1b pro-
duction and reduced steatosis and ﬁbrosis without preventing
liver injury [112].
Potential molecular triggers for inﬂammasome activation in
NASH include DAMPs such as DNA, saturated fatty acids, and648 Journal of Hepatology 201PAMPs (LPS). In primary hepatocytes, saturated, but not unsatu-
rated fatty acids induce caspase-1 activation and IL-1b release
in the presence of LPS [66]. Furthermore, we have recently dem-
onstrated that danger signals from fatty acid-treated hepatocytes
can induce inﬂammasome activation in liver mononuclear cells
[66], suggesting a crosstalk between liver parenchymal cells
and immune cells in NASH (Fig. 4) This intercellular crosstalk
provides potential ampliﬁcation of inﬂammasome activation
and inﬂammatory pathways in NASH. Observations from
MyD88 KO and TLR9 KO mice, where steatohepatitis was attenu-
ated in a CDAA-diet model, lead to the hypothesis that apoptotic
DNA from damaged cells is sensed by TLR9 that triggers IL-1b
mRNA transcription, while other DAMPs activate the inﬂamma-
some [74]. Fatty acid-induced inﬂammasome activation in mac-
rophages was NLRP3-dependent and involved increased
mitochondrial ROS production and decreased autophagy due to
reduced AMPK activity [115]. The role of ceramide was also
reported in fatty acid-induced inﬂammasome activation [113].
IL-1b promoted the development of hepatic steatosis via sup-
pression of peroxisome proliferator-activated receptor a (PPARa)
activity [116] but it also increased cell death in lipid-loaded
hepatocytes [74]. Petrasek et al. found that IL-1b increased the
hepatotoxic effect of TNFa [119]. Thus, the crosstalk between
TLR and inﬂammasome activation is another important determi-
nant of steatohepatitis and the inﬂammatory response in the
liver.
Understanding the cell-speciﬁcity of inﬂammasome activation
in fatty liver disease has implications for future potential thera-
peutic approaches. An important role for Kupffer cells is sup-2 vol. 57 j 642–654
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JOURNAL OF HEPATOLOGYported by the fact that these cells exhibited the highest levels of
IL-1b mRNA among liver cell types, and depletion of Kupffer cells
markedly decreased liver mRNA and serum IL-1b levels [74,116].
Selective deﬁciency in IL-1b or IL-1a in liver parenchymal cells,
but not in bone-marrow-derived cells, protected mice from
diet-induced steatohepatitis and ﬁbrosis [114]. These observa-
tions suggest that inﬂammasome and IL-1b production by differ-
ent cell types contribute to different aspects of steatohepatitis.
Translation of ﬁndings from animal models to human NASH
has limitations. Increased mRNA expression of NLRP3 inﬂamma-
some components was found in human livers of NASH patientsJournal of Hepatology 201[66] as well as in abdominal fat of obese patients with type 2 dia-
betes [117] where NLRP3 levels were decreased after weight loss
[117]. Interestingly, others found that while weight loss did not
inﬂuence liver and adipose tissue NLRP3 expression, the hepatic
IL-1b, IL-18, and IL-Ra levels were signiﬁcantly reduced [120].
The lack of an animal model that mimics all features of human
NASH challenges translation of speciﬁc ﬁndings from animals to
humans. For example, MyD88 deﬁciency prevented CDAA-
induced NASH in one study and [74] it worsened the HF diet-
induced steatohepatitis in another study [121]. Further studies
are needed to provide clariﬁcations.2 vol. 57 j 642–654 649
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Viral hepatitis
IL-1b levels are increased in patients with chronic HCV infection
and these levels are even higher in those with cryoglobulinaemia
[122–124]. Serum IL-1b and caspase-1 levels are decreased in
those individuals who respond to anti-HCV therapy [122]. The
cellular source of IL-1b in HCV infection is yet to be determined.
Kupffer cells have been described as a source of IL-1b because
HCV proteins induced IL-1b, TNFa, and IL-10 production from
KCs [124,125]. Recently, Burdette et al. have reported NLRP3
inﬂammasome activation and IL-1b production from HCV
infected human hepatoma cells (JFH1) [67]. Notably, HCV core
protein downregulated caspase-1 and caspase-4 in human B lym-
phocytes [126]. We found increased expression of NLRP3 inﬂam-
masome at the mRNA level in livers of patients with chronic
hepatitis C infection suggesting that inﬂammasome upregulation
may be a component of HCV immunopathology [66].
Hepatitis B virus (HBV) core antigen induced caspase-1-
dependent IL-18 secretion from human PBMCs and IL-18 levels
were increased in PBMCs from HBeAg negative patients, suggest-
ing the possibility of inﬂammasome activation in chronic HBV
infection [127]. Inﬂammasome involvement in other viral dis-
eases [128] and involvement of the RIG-I pathway in IL-1b pro-
duction [50] suggest that inﬂammasomes may play role in HCV
and other forms of viral hepatitis.
Liver ﬁbrosis
Chronic liver inﬂammation, that is ampliﬁed by IL-1, leads to
ﬁbrosis and cirrhosis. In rats, IL-1Ra administration attenuated
dimethylnitrosamin (DMN)-induced liver cirrhosis [129] and IL-
1R-deﬁcient mice were protected from thioacetamide (TAA)-
induced ﬁbrogenesis [130]. The expression of MMP9, MMP13,
and TIMP, regulators of ﬁbrosis and tissue remodeling, is IL-1-
dependent [130]; however, the exact mechanisms by which IL-
1R signaling promotes ﬁbrosis and the cell type(s) that pro-
duce(s) IL-1b are yet to be fully deﬁned. Hepatic stellate cells
expressed components of the inﬂammasome and activation of
primary mouse stellate cells or LX-2 HSC cells with MSU resulted
in increased TGFb and collagen-1 expression, actin reorganiza-
tion, and inhibition of HSC chemotaxis in an NLRP3-dependent
manner [69]. In a carbon-tetrachloride (CCl4) and TAA-induced
in vivo liver ﬁbrosis model, expression of TGFb and collagen-1
was signiﬁcantly reduced in mice lacking either NLRP3 or the
adaptor molecule ASC [69]. Additional data from the CCl4-
induced ﬁbrosis model indicated that IL-1Ra protected mice from
acute hepatocyte damage and promoted hepatocyte proliferation
[131]. In an animal model of NASH, inhibition of hepatic cell
death with a pan-caspase inhibitor suppressed ﬁbrosis [112].
The speciﬁc role of caspase-1 versus other caspases is yet to be
fully understood in liver ﬁbrosis.
Other liver diseases
While the characterization of the role of inﬂammasomes in auto-
immune hepatitis is still under investigation, increased serum IL-
1b levels were found in patients with primary biliary cirrhosis
(PBC) [132].
Although parasitic schistosomiasis is rare in the Western
world, it is common in Africa, Asia, and South America. Schisto-
soma mansoni egg antigens were shown to induce NLRP3 inﬂam-650 Journal of Hepatology 201masome activation and IL-1b secretion from macrophages via
Dectin-2, ROS production and potassium efﬂux [133], and
NLRP3-deﬁcient mice exhibited decreased immunopathology
and smaller granulomas following S. mansoni infection [133].
IL-1b gene polymorphisms were found to inﬂuence the sus-
ceptibility of developing HCC in chronic liver diseases [134].
Another study found that caspase-1 expression was downregu-
lated in hepatocellular carcinoma [135]. However, Yan et al.
found higher caspase-1 activity both in human HCC and in hepa-
toma cell lines exposed to hypoxia [68]. In addition, IL-18 has
been reported to promote hepatic metastases of melanoma via
the adhesion molecule VCAM-1 [136].
IL-1 and inﬂammasome activation may be related to compli-
cations of liver diseases. For example, in addition to contribut-
ing to the development of liver injury, inﬂammation and
ﬁbrosis, IL-1b, IL-18, and the inﬂammasomes may also mediate
encephalopathy. Caspase-1 and IL-18 levels were higher in
patients with acute or acute-on-chronic liver failure compared
to controls or patients with stable chronic liver diseases [137].
Furthermore, the onset of hepatic encephalopathy in toxic liver
injury was delayed in IL-1R KO mice [138]. The role of local
inﬂammasome activation and IL-1b in the brain was demon-
strated in various forms of cognitive and brain diseases, such
as Alzheimer’s disease, and in alcohol-related behavioral
changes [16,139].
Finally, in auto-inﬂammatory syndromes, such as the macro-
phage activation syndrome (MAS), hepato-splenomegaly and
abnormal liver function tests can occur and some of these auto-
inﬂammatory diseases improve with anti-IL-1 therapy [53]. Case
reports documented successful treatment of MAS with anakinra
[140], however, in some rare cases, the onset of MAS [141] or
acute hepatitis has also been reported after anakinra therapy
[142].Caveats in the evaluation of inﬂammasome activation in liver
diseases
While the involvement of NLRs, inﬂammasome activation and IL-
1b is increasingly evident in various forms of liver diseases, sev-
eral additional concepts deserve consideration.
Key Points 6 
There are caveats in the evaluation of the role of 
ASC
inflammasomes in liver diseases which include the
alternative cleavage of IL-1β, the tissue-/cell-specific
distribution and role of inflammasomes and the
inflammasome-independent role of the adaptor moleculeAlternative pathways of IL-1b cleavage
While caspase-1 is the most important enzyme involved in the
cleavage of pro-IL-1b into its mature form, other enzymes such
as caspase-8 [143] and neutrophil- and macrophage-derived ser-
ine proteases [144,53] cleave pro-IL-1b. This may explain that
while IL-1b deﬁciency prevented inﬂammation in some sterile2 vol. 57 j 642–654
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inﬂammation models, the lack of caspase-1 was not protective
[144]. In addition, the functional importance of IL-1b and IL-18
may be distinct in different tissues and cell types. This notion is
supported by recent data suggesting a prominent role for IL-18
in intestinal homeostasis, while IL-1b seems to play a bigger role
in liver diseases.
Tissue- and cell-speciﬁc expression and role of inﬂammasomes
Given the multiple functions and distinct tissue and cell distribu-
tion [36] of the inﬂammasomes, they may have different roles in
different tissues. For example, while inﬂammasomes and cas-
pase-1 induced cell death, pyroptosis, and pyronecrosis in macro-
phages, caspase-1 was found to promote cell survival in HeLa and
CHO cell lines [22]. Moreover, even though the NLRP3 inﬂamma-
some is important for the maintenance of the intestinal barrier
and protection against colitis [145], it can still contribute to
inﬂammation in gut immune cells. Cell speciﬁcity of inﬂamma-
somes has particular relevance to liver diseases where increased
gut permeability contributes to the pathogenesis.
ASC is not just a passive adaptor
ASC is necessary for the formation of many (but not all) inﬂam-
masome complexes. There is increasing evidence that ASC has
inﬂammasome-independent functions, for example in lympho-
cyte migration and antigen presentation of dendritic cells [146]
as well as in regulation of MAPK activity and chemokine expres-
sion [147].
‘‘Non-canonical’’ functions of caspase-1 [56]
Beyond its role in IL-1b, IL-18, IL-33 cleavage, regulation of cas-
pase-7, and cell death, caspase-1 was shown to be necessary for
release of HMGB1, a major DAMP [148].
Caspase-11 in non-canonical inﬂammasome activation
Recently, Kayagaki et al. have reported that caspase-11 (human
caspase-4 and -5) triggers caspase-1-independent macrophage
death and caspase-1-dependent IL-1b and IL-18 production in
response to certain inﬂammasome activators, including CTB,
Escherichia coli, Citrobacter rodentium, Vibrio cholera [149].
NLRP6: a ‘‘new’’ inﬂammasome
To date, mostly four main prototypes of inﬂammasomes have
been characterized, but there are other NLRs, such as the recently
discovered NLRP6, that have uniquely increased levels in the liver
compared to the spleen [65]. Recent evidence suggests that
NLRP6 is a key component in the maintenance of epithelial cell
integrity [150] and its role in liver diseases associated with
increased gut permeability deserves investigations.Conﬂict of interest
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